Effect of TA-CIN (HPV 16 L2E6E7) booster immunisation in vulval intraepithelial neoplasia patients previously vaccinated with TA-HPV (vaccinia virus encoding HPV 16/18 E6E7)
- 19 February 2004
- Vol. 22 (21-22) , 2722-2729
- https://doi.org/10.1016/j.vaccine.2004.01.049
Abstract
No abstract availableKeywords
This publication has 16 references indexed in Scilit:
- Cervical Cancer Vaccines: Recent Advances in HPV ResearchViral Immunology, 2003
- VIN 3: a clinicopathologic reviewInternational Journal of Gynecologic Cancer, 2002
- Enhancement of human papillomavirus (HPV) type 16 E6 and E7-specific T-cell immunity in healthy volunteers through vaccination with TA-CIN, an HPV16 L2E7E6 fusion protein vaccineVaccine, 2002
- Pre-clinical safety and efficacy of TA-CIN, a recombinant HPV16 L2E6E7 fusion protein vaccine, in homologous and heterologous prime-boost regimensVaccine, 2001
- Clinical studies of human papilloma vaccines in pre-invasive and invasive cancerVaccine, 2001
- The Makings of a Tumor Rejection AntigenImmunity, 1999
- Construction and characterisation of a recombinant vaccinia virus expressing human papillomavirus proteins for immunotherapy of cervical cancerVaccine, 1996
- A recombinant vaccinia virus encoding human papillomavirus types 16 and 18, E6 and E7 proteins as immunotherapy for cervical cancerThe Lancet, 1996
- Vulval intraepithelial neoplasia—management and outcomeBJOG: An International Journal of Obstetrics and Gynaecology, 1989
- Vulvar intraepithelial neoplasia and microinvasive carcinoma of the vulva.Journal of Clinical Pathology, 1984